The site-specific conjugation technology of NewBio Therapeutics can conjugate the small molecule drugs to antibody site-specifically, and thus give ADC products with high homogeneity. Based on this innovative site-specific conjugation technology, there is no need to conduct tedious genetic engineering modification to create an antibody with controlled conjugation sites, and the conjugation process is simple, fast and controllable. The highly homogeneous ADC products based on this technology have improved in-vivo stability, decreased toxicity, and improved anti-cancer potency.
1. BiM Technology
For IgG1 type antibody, BiM technology can provide ADC products bearing an average DAR value around 4, with the DAR4 fractions being the main components (>85%).
2. TriM Technology
For IgG1 type antibody, TriM technology can provide ADC products bearing an average DAR value around 3, with the DAR3 fractions being the main components (>85%).
3. TetraM Technology
For IgG1 type antibody, TetraM technology can provide ADC products bearing an average DAR value around 2, with the DAR2 fractions being the main components (>85%).